NeurAxis, Inc.
AMEX:NRXS · New York Stock Exchange American
+$0.29 today
Vol 0.13M · Avg 0.18M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
AMEX:NRXS · Revenue to Net Income
Key Ratios
Analysis
$4.3M of revenue converted into -$7.3M of net income for the selected period. Gross margin is 84.7% and net margin is -184.2%, showing how much revenue survives after costs and taxes. EPS is $-0.80, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M +32.9% | $2.7M +9.2% | $2.5M -8.4% | $2.7M -1.3% | $2.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $562.9K +55.5% | $362.0K +19.3% | $303.3K +2.1% | $297.1K -36.5% | $467.7K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.0M +29.4% | $2.3M +7.8% | $2.2M -9.7% | $2.4M +5.9% | $2.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 84.2% -2.3pp | 86.5% -1.1pp | 87.7% -1.3pp | 88.9% +6.1pp | 82.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $493.6K +139.5% | $206.1K +21.7% | $169.3K -25.0% | $225.6K +10.9% | $203.4K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $10.3M +11.5% | $9.3M +7.2% | $8.7M +56.3% | $5.5M +10.2% | $5.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $10.8M +14.3% | $9.5M +7.5% | $8.8M +53.1% | $5.8M +10.3% | $5.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $59.5K +57.3% | $37.8K -7.1% | $40.7K +9.7% | $37.1K +1.2% | $36.7K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$7.7M +3.0% | -$7.9M +14.4% | -$9.2M -113.3% | -$4.3M -46.4% | -$3.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -214.8% +79.4pp | -294.2% +80.9pp | -375.1% -214.0pp | -161.1% -52.5pp | -108.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$7.8M -9.4% | -$7.2M -7.4% | -$6.7M -97.6% | -$3.4M -13.5% | -$3.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -219.4% +47.1pp | -266.5% +4.5pp | -270.9% -145.3pp | -125.6% -16.5pp | -109.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 +100.0% | -$2.8K +99.9% | -$2.3M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $74.0K -75.4% | $300.7K -94.4% | $5.4M +1183.1% | $417.6K +1030.9% | $36.9K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $29.4K +102.7% | -$1.1M +86.4% | -$8.0M -465.6% | -$1.4M -2327.4% | -$58.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$7.8M +5.4% | -$8.2M +43.7% | -$14.6M -206.0% | -$4.8M -57.9% | -$3.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -218.5% +88.3pp | -306.8% +287.7pp | -594.6% -416.5pp | -178.0% -66.8pp | -111.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$7.8M +5.4% | -$8.2M +43.7% | -$14.6M -206.0% | -$4.8M -57.9% | -$3.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -218.5% +88.3pp | -306.8% +287.7pp | -594.6% -416.5pp | -178.0% -66.8pp | -111.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +22.1% | -$1 +47.4% | -$2 -307.0% | -$1 +8.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +22.1% | -$1 +47.4% | -$2 -197.4% | -$1 -25.8% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $9.1M +31.3% | $6.9M +9.9% | $6.3M -25.2% | $8.4M +56.3% | $5.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $9.1M +31.3% | $6.9M +9.9% | $6.3M -25.2% | $8.4M +56.3% | $5.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Rallybio Corporation
NASDAQ:RLYB
$92.36M
Minerva Neurosciences, Inc.
NERV
$29.51M
Klotho Neurosciences, Inc.
KLTO
$20.08M
NeuroSense Therapeutics Ltd.
NRSN
$18.50M
Exicure, Inc.
XCUR
$15.52M
Enlivex Therapeutics Ltd.
ENLV
$15.06M
TAO Synergies Inc.
TAOX
$12.15M
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$9.35M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
CollPlant Biotechnologies Ltd.
CLGN
$4.03M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NRXS generate?
NeurAxis, Inc. (NRXS) reported $3.57M of revenue in fiscal 2025.
Is NRXS profitable?
NeurAxis, Inc. (NRXS) reported -$7,800,555.00 of net income, with a net margin of -218.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.